Faron Pharmaceuticals

Faron Pharmaceuticals specializes in developing drugs that target endothelium receptors. These blood vessel-found proteins assist in regulating the immune response. The business is currently working on two small molecule therapeutic candidates that have the potential to treat a variety of illnesses, such as cancer, infectious diseases, respiratory ailments, and multi-organ failure. The phase III acute respiratory distress syndrome studies for the most advanced program are now complete.

Acute Respiratory Distress Syndrome (ARDS) is a condition that is treated with the company's flagship medication, Traumakine. After an open-label, early-phase trial produced encouraging results in the treatment of patients with ARDS, it is currently (2020) undertaking worldwide phase III clinical trials. Vascular leakage and the escalation of inflammation are decreased as a result of the medication's ability to increase lung CD73 expression and increase the synthesis of the anti-inflammatory compound adenosine. The planned protocol design for the next Traumakine research, which will begin in March 2020, has been approved by the U.S. Food and Drug Administration FDA. The phase III trial compares the effectiveness of several treatments for ARDS patients. Faron Pharmaceuticals is one of the largest biotech companies in Finland.

Headquarters: Turku

Founded: 2003

Website: https://www.faron.com/